Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.
Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, Schmeiser T, Strangfeld A, Voll RE, Krause A, Reckert S, Gräßler A, Saar P, Kapelle A, Backhaus M, Blank N, Henes J, Osiek S, Knothe A, Hoese G, Brandt-Jürgens J, Maltzahn A, Specker C, Müller-Ladner U, Schulze-Koops H; COVID-19 task force of the German Society of Rheumatology collaborators; COVID19-Rheuma.de collaborators. Hasseli R, et al. RMD Open. 2023 Apr;9(2):e002998. doi: 10.1136/rmdopen-2023-002998. RMD Open. 2023. PMID: 37068915 Free PMC article.
Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis.
Rohde M, Kernder A, Acar H, Düsing C, Fischer-Betz R, Haase I, Mucke J, Sander O, Richter J, Filla T, Schneider M, Chehab G. Rohde M, et al. Among authors: fischer betz r. Front Med (Lausanne). 2023 Feb 9;10:1107148. doi: 10.3389/fmed.2023.1107148. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36844213 Free PMC article.
First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104.
Iking-Konert C, Stocks S, Weinsberg F, Engelbrecht R, Bleck E, Perniok A, Fischer-Betz R, Pincus S, Nardone L, Schneider M. Iking-Konert C, et al. Ann Rheum Dis. 2004 Sep;63(9):1104-12. doi: 10.1136/ard.2003.016691. Ann Rheum Dis. 2004. PMID: 15308520 Free PMC article. Clinical Trial.
[Systemic lupus erythematosus].
Fischer-Betz R, Herzer P, Schneider M. Fischer-Betz R, et al. Dtsch Med Wochenschr. 2005 Oct 28;130(43):2451-8; quiz 2459-60, 2461-2. doi: 10.1055/s-2005-918589. Dtsch Med Wochenschr. 2005. PMID: 16240245 Review. German. No abstract available.
[Modern therapy for systemic lupus erythematosus].
Fischer-Betz R, Schneider M. Fischer-Betz R, et al. Z Rheumatol. 2007 Dec;66(8):662-6, 668-71. doi: 10.1007/s00393-007-0234-9. Z Rheumatol. 2007. PMID: 18000668 Review. German.
119 results